Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dual-Eligible Switch Poses New Barriers To Drug Access – Consultant

Executive Summary

Low-income seniors may face new barriers to obtaining prescription drugs after Medicare assumes responsibility for their coverage, Southeastern Consultants President Mary Kay Owens said at an IIR Medicaid conference in Denver

You may also be interested in...



Auto-Enrolling Dual-Eligibles Should Precede Medicare Rx– PhRMA

The Centers for Medicare & Medicaid Services should automatically assign dual-eligibles to Medicare prescription drug plans once enrollment begins, the Pharmaceutical Research & Manufacturers of America recommends in comments to the agency

Auto-Enrolling Dual-Eligibles Should Precede Medicare Rx– PhRMA

The Centers for Medicare & Medicaid Services should automatically assign dual-eligibles to Medicare prescription drug plans once enrollment begins, the Pharmaceutical Research & Manufacturers of America recommends in comments to the agency

USP Working Toward Medicare Formulary PBMs Can Use, McClellan Says

U.S. Pharmacopeia will make sure its model Medicare formulary guidelines "work" for prescription drug plan sponsors as it constructs the final version, Centers for Medicare & Medicaid Services Administrator Mark McClellan says

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044753

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel